Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 40 results
Filters: First Letter Of Title is A  [Clear All Filters]
Found 40 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

A

Demeter LM, Degruttola V, Lustgarten S, et al. "Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience." HIV Clin Trials. 2008;9(1):11-25.
McLinden RJ, Paris RM, Polonis VR, et al. "Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170)." AIDS. 2012;26(1):1-9.
Kang M, Cu-Uvin S. "Association of HIV viral load and CD4 cell count with human papillomavirus detection and clearance in HIV-infected women initiating highly active antiretroviral therapy." HIV Med.. 2012;13(6):372-8.
Cohn SE, Jiang H, J McCutchan A, et al. "Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362." AIDS Care. 2011;23(6):775-85.
McLaren PJ, Coulonges C, Ripke S, et al. "Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls." PLoS Pathog.. 2013;9(7):e1003515.
Foulkes AS, Wohl DA, Frank I, et al. "Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy." PLoS Med.. 2006;3(3):e52.
McComsey GA, Kitch D, Sax PE, et al. "Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202." J. Acquir. Immune Defic. Syndr.. 2014;65(2):167-74.
Taiwo B, Matining RM, Zheng L, et al. "Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy." J. Antimicrob. Chemother.. 2013;68(8):1857-61.
Daar ES, Tierney C, Fischl MA, et al. "Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1." Ann. Intern. Med.. 2011;154(7):445-56.
Connick E, Bosch RJ, Aga E, Schlichtemeier R, Demeter LM, Volberding P. "Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection." J. Acquir. Immune Defic. Syndr.. 2011;58(1):1-8.

Pages